JPMorgan Tweaks Hims & Hers Stock Outlook on Key Risk
Hims & Hers Health NYSE:HIMS faces a more complicated growth path as regulatory pressure reshapes its weight-loss business, prompting JPMorgan to resume coverage at Neutral with a $32 price target. The target implies roughly 17% upside from the Sept. 10 close, but the bank wants clearer evidence th…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.